The research combined a multicenter contouring exercise with a retrospective recurrence-mapping analysis. Ten radiation oncologists from eight centers independently delineated the prostate-bed CTV in one postoperative case. Agreement was summarized using the Dice similarity coefficient, or DSC, and the 95th-percentile Hausdorff distance, or HD95. The mean pairwise DSC was 0.767 ± 0.046, and the mean HD95 was 8.244 ± 2.347 mm. The investigators reported considerable interobserver variation, particularly around the bladder. Because the exercise involved a single postoperative case, the measurements characterize agreement for that case rather than the full anatomical and clinical variation encountered in routine practice.

For the recurrence analysis, the investigators assigned PSMA PET-positive prostate-bed lesions to an exploratory framework containing six anatomical zones. In addition to the bladder-neck and vesicourethral anastomotic regions, the retrovesical area, Zone 5b, contained 17 of 97 events, or 17.5%, and the dorsolateral perivesical region, Zone 5a, contained 12 events, or 12.4%. The cranial seminal-vesicle-bed region, Zone 6, contained seven events, while the ventral perivesical region, Zone 4, contained only two of 97 events, or 2.1%. The observed maximum extents were 1.3 cm for the 12 Zone 5a events and 3.0 cm for the seven Zone 6 events. These figures describe the extent of recurrence observed in this sample; they do not establish universally safe CTV boundaries or predict recurrence patterns in all patients after surgery.

The researchers also assessed whether recurrence centroids were covered by CTV definitions from the ESTRO-ACROP 2023, GFRU 2020, and RTOG 2010 guidelines. At the patient level, all identified recurrence centroids were covered in 54 of 63 patients by ESTRO-ACROP, or 85.7% (95% confidence interval, 75.0%–92.3%). Coverage was 52 of 63 patients, or 82.5% (95% confidence interval, 71.4%–90.0%), for GFRU and 53 of 63 patients, or 84.1% (95% confidence interval, 73.2%–91.1%), for RTOG. These results are centroid-based assessments and therefore do not demonstrate that every portion of every recurrence was contained within the corresponding CTVs.

Overall, the study found that PSMA PET-positive recurrences were unevenly distributed within the prostate bed after radical prostatectomy and that radiation oncologists showed notable variation when contouring postoperative targets. The low event count in the ventral perivesical region provides an imaging-based rationale for further evaluation of CTV boundaries in that area, while the contouring results underscore the variation around the bladder. The findings may help inform future studies of postoperative target-volume refinement, but the authors emphasized that validation in larger multicenter cohorts is required. The study did not test whether changing any guideline boundary would improve clinical outcomes, and the contouring exercise and retrospective recurrence analysis do not establish a causal effect of CTV size on recurrence or treatment success.

Subject of Research: Postoperative prostate-bed recurrence mapping and radiation target-volume delineation

Article Title: PSMA PET recurrence mapping and guideline coverage after radical prostatectomy: implications for postoperative prostate bed CTV delineation

Article References: Qi, X., Zhang, H., Chen, C., Wu, J., Liao, X., Zhang, J., He, L., Lu, N., Shen, Y., Wang, H., Zhong, Q., Li, Y., Zhang, M., Gao, X., & Li, H. (2026). PSMA PET recurrence mapping and guideline coverage after radical prostatectomy: implications for postoperative prostate bed CTV delineation. BMC Medical Imaging. https://doi.org/10.1186/s12880-026-02931-x

Image Credits: AI Generated

DOI: 10.1186/s12880-026-02931-x

Keywords: PSMA PET, prostate cancer, radical prostatectomy, prostate bed, recurrence mapping, salvage radiotherapy, clinical target volume, radiation oncology, interobserver variation, guideline coverage, PSMA, recurrence

The patients were not an easy crowd. All had presented with high-risk features at initial diagnosis: the median biopsy Gleason score clustered at 8, more than 42 percent had extraprostatic extension (pT3b), 20 percent already harbored positive lymph nodes at surgery, and over a third had incomplete resections. Yet when their prostate-specific antigen (PSA) began climbing after first-line therapy, modern gallium-68 or fluorine-18 PSMA-PET/CT scans pinpointed the culprits — 172 metastases in total, roughly 80 percent nodal and 20 percent bone — while disease burden remained low, with a median pre-SBRT PSA of just 1.66 ng/mL.

The treatment itself was strikingly uniform. Each PSMA-avid lesion defined the gross target volume, wrapped in a 1-to-5-millimeter planning margin depending on location, and received an ablative dose to the surrounding 70 percent isodose line of either a single 18-to-21-Gy fraction or three 8-Gy fractions. The CyberKnife robotic platform tracked lesions stereoscopically — bone tracking in 92.4 percent of cases, fiducial markers in the rest — allowing sub-millimeter accuracy that spared surrounding bowel, bladder, and spinal cord. Most series treated one or two metastases; the median planning target volume was a mere 3.31 cubic centimeters.

Toxicity data read like a wish list. Across 95 treatment series, 93.5 percent of patients experienced no acute or late adverse events at all. The six acute grade 1 events comprised temporary fatigue, diarrhea, nausea, and single cases of pain, proctitis, and polyuria; only one patient developed a late symptom, a persistently painful bone metastasis. No event exceeded grade 1. That stands in sharp contrast to trials combining SBRT with elective nodal radiation or hormone therapy, where grade 2 and 3 genitourinary and gastrointestinal toxicity rates have reached double digits, and to systemic therapy arms in the STAMPEDE and LATITUDE trials, where 47 to 63 percent of patients suffered grade 3 or worse adverse events.

Local control was equally impressive. Among 117 metastases re-assessed by repeat PET/CT, 89.7 percent remained locally controlled — 93.5 percent for lymph nodes but only 76 percent for bone lesions. The authors attribute the nodal-bone gap to the protective microenvironment of the bone marrow, which shelters cancer cells, and possibly to hypoxia within bone lesions, which blunts radiation efficacy. PSA response after SBRT was seen in 70.5 percent of series, with the median post-treatment nadir falling to 0.58 ng/mL roughly four months after treatment.

The headline endpoints tell the story of a bridge. Median biochemical progression-free survival was 6 months — short by conventional standards, but the strict definition used (a PSA rise of more than 0.2 ng/mL from nadir) and the aggressive histology of the cohort (63 percent with Gleason 8 or higher) make direct comparisons tricky. Median SBRT-free survival, meaning the time before a second course became necessary, was 23 months, and 43 of the 60 patients actually received repeat SBRT courses with no predefined upper limit. Median ADT-free survival reached 32 months, with 85.9 percent of patients still hormone-free at one year and 68.4 percent at two years. A third of the cohort finished follow-up without any treatment escalation whatsoever.

Prognostic modeling identified who fared worst. A high PSA nadir after SBRT, an initial pN1 nodal status at surgery, and a longer time to reach the PSA nadir all predicted shorter biochemical progression-free and SBRT-free survival on multivariable Cox regression. The authors suggest these patients could be steered earlier toward combination approaches — either standard ADT or androgen receptor pathway inhibitors such as abiraterone, enzalutamide, apalutamide, or darolutamide — rather than cycling through repeated focal treatments that may ultimately prove futile.

The rationale for attacking metastases this early rests on evolutionary biology. Genetic analyses of lethal metastatic prostate cancer have shown that the tumor clones responsible for fatal dissemination do not necessarily reside in the primary tumor but can emerge from any single metastasis. Meanwhile, early metastases detected by molecular imaging carry fewer high-risk DNA features and a better survival prognosis than those found later. The logic, then, is to intervene while the disease is still genetically tame — and to save the effective but toxic and finite systemic arsenal for when it is truly needed.

The Charité results compare favorably with prior prospective trials. The STOMP trial reported a median ADT-free survival of 21 months; Siva and colleagues described only a 48 percent two-year ADT-free rate; Mazzola’s bone-only cohort managed 13.5 months. The Berlin cohort’s 32-month median, achieved without ADT contamination and with a uniform ablative dose concept, is among the best reported. The second-largest number of metastases treated in any single analysis also strengthens the dataset, though the authors acknowledge the retrospective design, the absence of a control arm, and the lack of a predefined PSA cutoff triggering re-imaging or re-treatment as critical limitations.

Whether early oligo-recurrences inevitably progress into life-threatening disease remains an open question, and the authors concede that for some patients with gradual progression, observation might have sufficed. Still, they argue that establishing molecular imaging plus focal SBRT as a first go-to option in oligo-recurrent prostate cancer is worthwhile: the procedure is swift, outpatient-based, locally ablative, essentially toxicity-free, and repeatable on demand. For patients anxious about the quality-of-life toll of permanent hormone therapy, the approach offers something rare in oncology — a way to buy nearly three years of normal testosterone levels while the clock on systemic therapy is deliberately held back.

Subject of Research: Health

Article Title: Bridging to systemic therapy: PSMA-PET-based early and repetitive stereotactic body radiotherapy for nodal and bone oligo-recurrent prostate cancer

Article References: Grün, A., Partyka, A., Galler, M., Schlomm, T., Böhmer, D., Miller, K., Zips, D., & Kalinauskaite, G. (2026). Bridging to systemic therapy: PSMA-PET-based early and repetitive stereotactic body radiotherapy for nodal and bone oligo-recurrent prostate cancer. Frontiers in Urology, 6, Article 1738508. https://doi.org/10.3389/fruro.2026.1738508

Image Credits: AI Generated

DOI: 10.3389/fruro.2026.1738508

Keywords: prostate cancer, PSMA-PET, SBRT, oligometastatic, radiation oncology, androgen deprivation therapy, metastasis-directed therapy, Charité Berlin, Bridging, systemic, therapy, PSMA-PET-based

The distinction between the two entities is anatomical and precise. Intraductal carcinoma of the prostate grows within pre-existing ducts and acini of the prostate, filling these spaces with malignant cells while retaining the layer of basal cells that lines normal glands. Invasive cribriform carcinoma, by contrast, breaks through into the surrounding stromal tissue and lacks those basal cells entirely. Both share a cribriform, or sieve-like, architecture in which nests of tumour cells are punctuated by round lumina, giving the tissue a characteristic perforated appearance under the microscope. Despite their histological differences, the two patterns are so frequently found together, and share such overlapping adverse biological features, that many researchers now regard them as points along a single aggressive continuum rather than as unrelated phenomena.

The clinical consequences of missing these patterns are substantial. Multiple studies reviewed by the authors show that IDC and invasive cribriform carcinoma are independently associated with cancer recurrence, metastasis and disease-specific mortality, even after accounting for grade group and stage. In Gleason score 7 tumours, the presence of cribriform growth has been shown to be highly predictive of postoperative metastasis and disease-specific death, and a secondary analysis of the landmark PROTECT trial found that outcomes for cribriform-positive men under active monitoring differed meaningfully from those of cribriform-negative patients. Yet a recent survey of tertiary referral institutions suggests that these so-called unconventional histologies are substantially under-reported, meaning that risk stratification tools, nomograms and clinical decision algorithms may systematically underestimate the aggressiveness of a subset of tumours that behave worst.

Perhaps the most troubling finding concerns detection. According to the review, biopsy identifies cribriform or intraductal patterns in only about half of the men who are subsequently found to harbour them at radical prostatectomy. This is not simply a matter of sampling error at the margins of a lesion; the discrepancy persists even in modern series using extended biopsy schemes. Magnetic resonance imaging-targeted sampling, which has transformed the detection of clinically significant prostate cancer more broadly, does not reliably close this gap. A systematic review and meta-analysis of multiparametric MRI found only modest diagnostic accuracy for unconventional histology, and studies of MRI-visible versus MRI-invisible tumours suggest that the molecular hallmarks of imaging visibility do not align neatly with cribriform biology. In other words, a man with a reassuring MRI and a grade group 2 biopsy may still be nursing an undetected cribriform component that changes everything about his prognosis.

Advanced imaging offers only partial consolation. Prostate-specific membrane antigen (PSMA) positron emission tomography combined with computed tomography provides indirect correlates of aggressive morphology and can improve staging, but it cannot directly determine tumour architecture. Intriguingly, research from Bernardino and colleagues has shown that intraductal carcinoma is overrepresented among patients with no PSMA uptake pattern on PET despite high-grade disease, exposing a genuine blind spot in molecular imaging. Other work has documented a lymphotropic pattern of metastatic spread among patients with cribriform disease, with PSMA-detected metastases preferentially involving lymph nodes. These findings suggest that neither MRI nor PSMA PET can substitute for pathological recognition of these morphologies, and that clinicians should treat a negative imaging study with caution when other features raise suspicion.

Beneath the microscope, these tumours carry a distinctive molecular fingerprint that helps explain their behaviour. Genomic studies have shown that cribriform and intraductal cancers are enriched for genomic instability, loss of the tumour-suppressor gene PTEN, and alterations in DNA-damage-repair genes, including associations with BRCA2 mutation. Single-cell analyses have revealed both cell-intrinsic and microenvironmental pathways of aggressive disease, and transcriptomic work has linked the subpathologies to dysregulation of drivers such as SChLAP1. Just as striking is the tumour microenvironment: cribriform prostate cancers are associated with immunologically cold niches, rich in fibroblasts and poor in infiltrating immune cells, a configuration that in other cancers has been associated with resistance to immunotherapy. Molecular evidence also supports a model in which invasive adenocarcinoma can colonize ducts in a retrograde fashion, and spatial mapping studies have documented intraductal-to-invasive transitions, giving rise to what the authors describe as a repetitive invasion, precursor progression model of intraductal carcinogenesis.

This biology has therapeutic implications, although the review is careful to draw a firm line between hypothesis and evidence. The enrichment for DNA-damage-repair alterations provides a rationale for evaluating PARP inhibitors, which have already shown benefit in metastatic castration-resistant prostate cancer in trials of olaparib. PTEN loss motivates interest in AKT pathway inhibition, exemplified by the phase III CAPItello-281 trial of capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive disease. Expression of B7-H3, also known as CD276, and of PSMA in intraductal carcinoma raises the possibility of targeting these antigens with antibody-drug conjugates or radioligand therapies such as lutetium-177 PSMA-617. However, the authors emphasize that no study has yet established that IDC or invasive cribriform morphology alone predicts benefit from any of these treatments. Morphology may flag a tumour worth testing molecularly, but it is not itself a validated predictive biomarker.

The treatment implications for localized disease are more immediately actionable. The review states plainly that known IDC or invasive cribriform carcinoma is generally a poor indication for active surveillance, and that focal therapy should be approached with caution. Because biopsy so often underestimates the extent and grade of these tumours, a patient selected for hemigland ablation on the basis of a favourable biopsy may in fact harbour multifocal, high-volume cribriform disease. Studies have shown that cribriform pattern and perineural invasion on fusion biopsy predict failure of selection criteria for prostatic hemigland ablation. Conversely, for patients undergoing definitive treatment, the presence of these morphologies should prompt consideration of treatment intensification, including extended pelvic lymph node dissection in surgical candidates, since cribriform architecture on needle biopsy is a strong independent predictor of lymph node metastasis.

Neoadjuvant data add a further layer of complexity. Retrospective analyses of prospective trials have found that intraductal carcinoma predicts poor response to neoadjuvant therapy in high-risk prostate cancer, and experimental work has shown that intraductal carcinoma can evade androgen deprivation with the emergence of castrate-tolerant cells. Genomic studies of tumours treated with intense hormonal therapy suggest that nascent heterogeneity drives evolution and resistance, with subclonal oncogenic alterations surviving the selective pressure of treatment. This may help explain why patients with IDC fare worse despite escalating systemic therapy, and it underscores the need for morphology-informed stratification in the design of neoadjuvant trials, several of which, including studies of apalutamide and darolutamide before surgery, are currently underway.

The review closes with a call for rigor that is as much about pathology reporting as it is about biology. Consensus definitions of cribriform pattern and of intraductal carcinoma have been established by the International Society of Urological Pathology and the Genitourinary Pathology Society, and interobserver reproducibility studies show that adherence to standardized criteria improves diagnostic consistency. The authors argue that explicit reporting of these morphologies in every pathology report, together with prospective morphology-informed clinical studies, is essential for accurate risk stratification, rational use of active surveillance and focal approaches, and the design of biomarker-driven trials for this aggressive disease subset. For a disease in which hundreds of thousands of men each year face decisions between watching and treating, the sieve-like patterns that pathologists see under the microscope may prove to be among the most consequential details in modern urological oncology.

Subject of Research: The role of cribriform and intraductal carcinoma morphologies in prostate cancer risk stratification and treatment decision-making

Article Title: Cribriform and intraductal carcinoma in prostate cancer — implications for risk stratification and therapeutic decision-making

Article References: Bernardino, R. M., Lobo, J., Schwen, Z., van der Kwast, T., Weiner, A. B., Reiter, R. E., Nguyen, J. K., Lima, E., Stein, R., Soputro, N., Ghandour, R., Beksac, A. T., Daher, K., Leão, R., Gonzalgo, M. L., van den Bergh, R., Garisto, J., Marra, G., Le Guévelou Kammerer, J., … Autorino, R. (2026). Cribriform and intraductal carcinoma in prostate cancer — implications for risk stratification and therapeutic decision-making. Nature Reviews Urology. https://doi.org/10.1038/s41585-026-01189-w

Image Credits: AI Generated

DOI: 10.1038/s41585-026-01189-w

Keywords: prostate cancer, intraductal carcinoma, cribriform carcinoma, pathology, biopsy, risk stratification, active surveillance, PSMA PET, PTEN, DNA damage repair, PARP inhibitors, tumor microenvironment

The core problem lies in what clinicians call the diagnostic gray zone. Serum prostate-specific antigen (PSA), the workhorse of prostate cancer screening since the early 1990s, loses much of its discriminative power when values fall between 4 and 10 ng/mL, a range where benign prostatic hyperplasia and prostatitis routinely elevate the marker just as aggressively as tumors do. Multiparametric MRI, the other pillar of modern triage, has its own blind spot: lesions graded PI-RADS category 3, the equivocal middle of the Prostate Imaging Reporting and Data System, carry genuinely ambiguous cancer probability. In this gray zone, the overlap between malignant and benign disease drives a substantial number of unnecessary biopsies—procedures that carry real morbidity, from bleeding and infection to the psychological burden of waiting, and that frequently detect indolent cancers a patient might never have needed to know about.

The review’s authors, led by Zijie Nie and corresponding author Lingling Wu, organize the emerging solutions into three broad categories: liquid-based molecular biomarkers, advanced imaging modalities, and integrative frameworks that fuse multiple data streams. On the biomarker front, the most mature tools refine what PSA already tells us. The Prostate Health Index (PHI), a mathematical combination of total PSA, free PSA, and the precursor form p2PSA, has been validated across European and Asian populations, with recent large Chinese cohort data confirming its utility and newer derivatives such as PHI density—PHI divided by prostate volume—outperforming PSA density in equivocal MRI settings. The 4Kscore, a four-kallikrein blood panel, has shown its worth as a reflex test after elevated PSA; in the GÖTEBORG-2 screening trial it performed well as a second-line discriminator, and the ProScreen randomized trial demonstrated that combining PSA, the kallikrein panel, and MRI can streamline screening pathways.

Perhaps the most conceptually elegant of the refined PSA tools is IsoPSA, which abandons concentration measurement altogether. Instead of asking how much PSA is in the blood, IsoPSA interrogates the structural heterogeneity of the PSA protein itself—cancerous tissue produces subtly different molecular forms of the enzyme than benign tissue does. Prospective multicenter validation showed improved detection of both any cancer and high-grade disease compared with conventional total PSA, and notably, its performance characteristics are unaffected by 5-alpha reductase inhibitors and alpha-blockers, drugs that confound standard PSA interpretation. A recent study further reported that IsoPSA density improves risk stratification and biopsy decision-making for clinically significant cancer.

Urine-based tests exploit a different biological logic: tumor-derived molecular signatures can be captured non-invasively from prostatic fluid expressed during a digital rectal examination or simply from first-catch urine. SelectMDx, a two-gene mRNA test, has been validated in prospective multicenter studies of biopsy-naïve men and compared directly against mpMRI in diagnostic meta-analyses. MyProstateScore (MPS), built around the TMPRSS2:ERG fusion gene and PCA3, has demonstrated a robust ability to rule out clinically significant cancer, including in men with equivocal PI-RADS 3 lesions—precisely the population where the clinical need is greatest. Its successor, MyProstateScore 2.0, an 18-gene urine test validated in JAMA Oncology, extends this approach to high-grade cancer detection using first-catch urine without any prior examination, removing a logistical barrier to widespread use.

Exosome technology represents a further step along the liquid biopsy frontier. The ExoDx Prostate IntelliScore test analyzes gene expression in urinary exosomes—nanoscale vesicles shed by prostate tissue—to predict high-grade cancer at initial biopsy in men with PSA between 2 and 10 ng/mL, with clinical performance confirmed across three independent prospective studies. Beyond RNA, researchers are mining exosomes for proteins and metabolites: proteomic profiling of urinary large extracellular vesicles, chemical affinity capture of plasma extracellular vesicles for large-scale biomarker discovery, and metabolomic fingerprints of vesicles from prostatic fluid all feature in the review as rapidly maturing avenues. Emerging candidates such as annexin A3, the homeobox protein engrailed-2 (EN2), CRISP3, and the cholinergic peptide SLURP1 add to a growing catalog of tumor-specific molecules detectable in urine.

MicroRNAs and metabolomics round out the molecular picture. Circulating and urinary microRNAs—including miR-21, miR-145, miR-30b-3p, and miR-375—have shown the ability to distinguish prostate cancer from benign lesions, with novel detection platforms such as silver nanoparticle sensors pushing toward point-of-care measurement. Metabolomics takes aim at the tumor’s altered biochemistry: sarcosine in urine, lipid species in exosomes, and serum metabolite panels have all discriminated cancer from benign prostatic hyperplasia within the PSA gray zone, and a recent systematic review of pre-diagnostic untargeted metabolomics supports their prospective value. The biological rationale is sound, since prostate cancer undergoes profound metabolic reprogramming, and metabolites often change earlier than structural imaging can detect.

On the imaging side, the review catalogues technologies that go beyond conventional mpMRI. Biparametric and abbreviated MRI protocols promise wider access with comparable detection accuracy. Magnetic resonance elastography measures the physical stiffness of tissue—cancers are typically harder than benign tissue—and tomoelastography based on multifrequency MRE has outperformed mpMRI in head-to-head comparisons. Amide proton transfer-weighted imaging, a chemical exchange saturation transfer technique, probes tissue pH and protein content at the molecular level and has added value to PI-RADS v2.1 in detecting clinically significant disease. Micro-ultrasound, with resolution roughly three times finer than standard ultrasound, performed comparably to MRI in biopsy-naïve men and was tested head-to-head against MRI-guided biopsy in the OPTIMUM randomized trial. Most striking is PSMA PET/CT, which images the prostate-specific membrane antigen expressed on tumor cells; studies such as PRIMARY have shown its additive value to mpMRI triage, and [18F]DCFPyL PET/CT has reduced unnecessary biopsies in PI-RADS 3/4 patients—though benign prostatic hyperplasia-related false positives remain its acknowledged Achilles’ heel.

The review’s central thesis, however, is that no single test will win. Instead, the field is converging on multimodal integration. Risk calculators such as Stockholm3—which combines protein biomarkers, genetic variants, and clinical variables—have been validated in multiethnic cohorts and combined productively with MRI. PSA density and PHI density refine biopsy thresholds when layered onto PI-RADS scores, and combining the PRIMARY score with PSA density helps avoid unnecessary biopsies after negative mpMRI. Artificial intelligence is the connective tissue of this shift: deep learning models detect clinically significant cancer on MRI with performance approaching that of expert radiologists, as demonstrated in the international PI-CAI study published in Lancet Oncology, while multimodal AI systems that fuse clinical data, biomarkers, and imaging inputs have improved detection beyond any single modality. Radiomics—high-throughput extraction of quantitative image features—adds another layer, with machine learning models predicting malignancy even in equivocal PI-RADS 3 lesions.

The implications for patients are concrete. By sharpening the boundary between cancer and its benign mimics before biopsy, these tools could spare thousands of men annually from invasive procedures that carry morbidity and psychological cost, while directing biopsies more precisely toward those with clinically significant disease. The authors emphasize that this is a paradigm shift from single-parameter screening to multimodal, AI-assisted decision-making—personalized risk stratification built from blood, urine, and image data. Challenges remain, including validation across diverse populations, cost, and clinical implementation, but the trajectory is clear: the diagnostic gray zone that has frustrated urologists for three decades is finally being mapped, molecule by molecule and pixel by pixel, and the biopsy needle may soon arrive only where it is truly needed.

Subject of Research: Non-invasive pre-biopsy diagnostic strategies for discriminating prostate cancer from benign prostatic diseases

Article Title: Recent advances in discriminating prostate cancer from benign prostatic diseases in the pre-biopsy population

Article References: Nie, Z., Zhu, T., Chen, Y., Zhang, W., & Wu, L. (2026). Recent advances in discriminating prostate cancer from benign prostatic diseases in the pre-biopsy population. Medical Oncology, 43(11), Article 305. https://doi.org/10.1007/s12032-026-03424-1

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03424-1

Keywords: prostate cancer, PSA, liquid biopsy, multiparametric MRI, biomarkers, PI-RADS, artificial intelligence, PSMA PET, urine tests, risk stratification, prostate biopsy, metabolomics

Metastatic castration-resistant prostate cancer, abbreviated mCRPC, is the lethal stage of prostate disease in which tumors continue to grow despite androgen-deprivation treatment. The arrival of [177Lu]Lu-PSMA-617, a radiopharmaceutical that delivers beta radiation directly to prostate cancer cells expressing the prostate-specific membrane antigen, changed the treatment landscape after the pivotal VISION phase III trial established it as a standard of care. Yet the survival benefit varies enormously from one patient to the next. Some men live for years after treatment begins, while others progress within months. Weighing the potential benefit against the burden of repeated nuclear medicine cycles demands an honest estimate of prognosis, and that is precisely what a validated scoring system can provide.

The Bellmunt Risk Score was originally developed for a completely different cancer: metastatic urothelial carcinoma. In its original setting, it stratified patients with advanced transitional cell carcinoma who had failed platinum-based chemotherapy using three binary variables that are universally available in any oncology clinic. Each patient receives one point for an Eastern Cooperative Oncology Group performance status greater than zero, meaning any degree of functional impairment; one point for anemia, defined as a hemoglobin concentration below 10 grams per deciliter; and one point for the presence of liver metastases. The resulting score ranges from zero to three, with higher scores indicating worse expected survival. Its elegance lies in its simplicity: no specialized software, no genomic sequencing, no additional laboratory panels.

In a recent primary analysis, the same research group showed that the score translates surprisingly well to prostate cancer patients undergoing PSMA-targeted radioligand therapy. But a demonstration in the development cohort is only the first step. Clinical prediction models are notorious for performing well in the population where they were built and then faltering elsewhere, a phenomenon statisticians call overfitting. External validation in a genuinely independent patient population, treated under different institutional pathways and evaluated by investigators uninvolved in the original data collection, is the mandatory test of generalizability. The new study was designed to meet exactly that standard.

The validation cohort comprised 243 men with confirmed PSMA-positive metastatic castration-resistant prostate cancer who received at least one cycle of [177Lu]Lu-PSMA-617 at University Hospital Frankfurt, a tertiary high-volume center with no patient overlap with the original development cohort. The score was calculated at baseline, within twenty-eight days before the first therapy cycle. The patient population was heavily pretreated: 9.9 percent received radioligand therapy as the first treatment line for metastatic disease, 22.6 percent as the second, 39.1 percent as the third, and 28.4 percent in even later lines. Over a median follow-up of 17.7 months, 111 deaths occurred, corresponding to 45.7 percent of the cohort, providing substantial statistical power for survival analysis.

The results revealed a strikingly clean stepwise pattern. Patients with a score of zero, meaning none of the three risk factors, had an estimated median overall survival of 24.0 months. Each additional point shaved months off that figure: 15.8 months for a score of one, 11.2 months for a score of two, and 8.7 months for the small group of seven patients with all three risk factors. The Kaplan-Meier comparison across the four groups was highly significant, with a log-rank p value below 0.0001. In univariable analysis, compared with the low-risk group, the hazard ratio for death was 1.63 for score one, 3.38 for score two, and 5.30 for score three, and these estimates aligned closely with the hazard ratios observed in the original development cohort.

Because more heavily pretreated patients naturally have worse survival, the researchers adjusted their multivariable analysis for the number of prior treatment lines. Even after this adjustment, the score remained an independent predictor of survival. The hazard ratio was 3.04 for score two and 4.76 for score three, both statistically significant, while score one showed a non-significant trend at 1.49. Given that only seven patients fell into the highest-risk category, the team performed a sensitivity analysis using Firth’s penalized likelihood Cox regression, a method designed for small sample sizes, which confirmed the stability of the estimate with a hazard ratio of 5.10.

Predictive accuracy was assessed with two complementary metrics. Harrell’s concordance index for the multivariable model combining the score and treatment line reached 0.659, comparable to the performance achieved in the development cohort. Time-dependent receiver operating characteristic analysis, which evaluates discrimination at specific time points, yielded area-under-the-curve values of 69.3 percent for six-month survival, 71.3 percent for twelve-month survival, and 67.5 percent for twenty-four-month survival. Calibration for twelve-month survival, examined with two hundred bootstrap resamples, was excellent, with a mean absolute error of just 0.027 and a maximum absolute error of 0.059, meaning the predicted and observed survival probabilities were nearly identical.

The authors are candid about the study’s limitations. The retrospective design and the absence of a central review of imaging data introduce potential bias, since liver metastases were identified through local institutional interpretation of PSMA PET/CT scans. The multivariable model deliberately adjusted only for treatment lines, omitting established prognostic markers such as baseline PSA, lactate dehydrogenase, alkaline phosphatase, and quantitative metastatic burden, which leaves open the possibility of residual confounding. The researchers argue that this restraint was intentional: adding complex variables would risk overfitting and would compromise the score’s identity as a strictly clinical, standalone, bedside-ready tool. The very small size of the score-three subgroup also demands cautious interpretation of its survival estimates.

What emerges is a pragmatic message for oncology. More sophisticated nomograms that incorporate quantitative PSMA-PET volume metrics or extended biochemical panels may theoretically offer superior accuracy, but they require specialized software or additional laboratory costs and are often impractical in routine care. The Bellmunt Risk Score, by contrast, can be computed in seconds from information already gathered at every oncology visit. As indications for [177Lu]Lu-PSMA-617 expand into earlier treatment lines following trials such as ENZA-p, which tested the radioligand in combination with enzalutamide, the need for rapid risk stratification will only grow. The researchers emphasize that the score is intended to complement, not replace, comprehensive clinical and imaging assessment, serving primarily to guide patient expectations and support shared decision-making. With external validation now complete, a tool born in urothelial carcinoma has earned a place in the prostate cancer clinic, offering clinicians and patients alike a clear-eyed, evidence-based starting point for one of the most consequential conversations in modern cancer care.

Subject of Research: External validation of the Bellmunt Risk Score for predicting overall survival in metastatic castration-resistant prostate cancer patients undergoing lutetium-177 PSMA-617 radioligand therapy

Article Title: External validation of the bellmunt risk score for survival prediction in mCRPC patients undergoing [177Lu]Lu-PSMA-617 therapy

Article References: Büttner, T., Wenzel, M., Mandel, P., Schmitt, P., Hoffmann, C., Marinova, M., Essler, M., Chun, F. K. H., Ritter, M., Groener, D., & Krausewitz, P. (2026). External validation of the bellmunt risk score for survival prediction in mCRPC patients undergoing [177Lu]Lu-PSMA-617 therapy. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-026-08169-7

Image Credits: AI Generated

DOI: 10.1007/s00259-026-08169-7

Keywords: metastatic castration-resistant prostate cancer, Bellmunt Risk Score, Lu-PSMA-617, radioligand therapy, survival prediction, prognostic markers, external validation, PSMA PET, overall survival, Kaplan-Meier analysis, Cox regression, nuclear medicine

The clinical problem the researchers set out to solve is deceptively simple to state but notoriously difficult to quantify. After surgical removal of the prostate, the earliest sign that cancer has returned is a rise in prostate-specific antigen, or PSA, the blood protein that gives biochemical recurrence its name. Roughly one in three patients in the study cohort eventually experienced this endpoint. But PSA alone is a lagging indicator: by the time it climbs, micrometastatic disease may already be established, and the window for effective salvage radiotherapy or androgen deprivation may have narrowed. Existing tools such as the CAPRA-S score, which combines pathological findings from the surgical specimen with PSA and Gleason grade, are useful but fundamentally retrospective, because they depend on tissue that can only be examined after the operation. A genuinely preoperative predictor would allow surgeons and radiation oncologists to plan adjuvant treatment strategies while the patient is still on the operating table.

The technology at the heart of the study is a hybrid imaging platform that simultaneously captures two complementary views of the same tumour. The PET component relies on 18F-PSMA-1007, a fluorine-18 labelled radioligand that binds to prostate-specific membrane antigen, a transmembrane enzyme overexpressed on the surface of nearly all prostate cancer cells. Because the tracer carries a positron-emitting isotope, its accumulation within a lesion is directly proportional to PSMA expression, which in turn correlates with tumour aggressiveness, hypoxia, and metastatic potential. The MR component provides high-resolution soft-tissue contrast, allowing precise delineation of tumour boundaries within the prostate and assessment of extracapsular extension. Performing both acquisitions in a single session eliminates the registration errors that plague separately acquired scans and yields co-registered datasets in which every voxel carries both metabolic and morphological information.

From these co-registered datasets the researchers extracted quantitative imaging features, a practice known as radiomics. Two derived parameters proved especially powerful. The first, ADCmin-TBR, combines the minimum apparent diffusion coefficient measured on diffusion-weighted MRI with the tumour-to-background ratio of PET tracer uptake. ADC reflects how freely water molecules diffuse through tissue: densely packed, aggressively proliferating tumour cells restrict water movement, driving ADC values down. TBR, by contrast, captures the metabolic intensity of the lesion relative to surrounding tissue. By multiplying or otherwise combining these two quantities, ADCmin-TBR effectively encodes a lesion that is both densely cellular and metabolically voracious, the hallmark of a tumour primed to recur. The second parameter, TMR, integrates tumour volume characteristics with metabolic activity, capturing the overall disease burden visible on the hybrid scan.

To build the model, the team divided their 210 patients into a training cohort of 150 and an external validation cohort of 60 drawn from different centres. Rather than hand-picking candidate predictors, they employed least absolute shrinkage and selection operator regression, or LASSO, coupled to a Cox proportional hazards framework. LASSO works by penalising model complexity, shrinking the coefficients of weak predictors toward zero and effectively eliminating them, which guards against overfitting in datasets where the number of variables approaches the number of events. The researchers used ten-fold cross-validation with the one-standard-error rule, a conservative criterion that selects the simplest model within one standard error of the best-performing one. Only three predictors survived this stringent selection: ADCmin-TBR, TMR, and the PET/MR-derived T-stage, an imaging-based assessment of how far the tumour has extended beyond the prostate capsule.

The performance figures are impressive for a purely preoperative tool. Time-dependent areas under the receiver operating characteristic curve, which measure discrimination at specific follow-up horizons, ranged from 0.703 to 0.858 in the training cohort and from 0.766 to 0.846 in the external validation cohort across the one-to-three-year window. An AUC of 0.85 at three years means the model correctly ranks a randomly chosen recurring patient above a randomly chosen non-recurring patient in 85 of 100 such pairs. Calibration plots confirmed that predicted probabilities matched observed recurrence rates, and inverse probability of censoring weighted Brier scores accounted for patients whose follow-up ended before the endpoint could be observed. Decision-curve analysis, which quantifies the net clinical benefit of acting on a model’s predictions across a range of risk thresholds, showed positive net benefit across most clinically relevant thresholds, suggesting the model could genuinely inform treatment decisions rather than merely describe risk.

Perhaps the most consequential finding concerns how the PET/MR model relates to the established CAPRA-S score. On its own, the imaging model did not significantly outperform CAPRA-S in raw discrimination, as DeLong tests revealed no statistically significant differences in AUC. But discrimination is not the only measure of a prognostic tool’s worth. When the researchers formally tested whether adding the PET/MR model to CAPRA-S improved the statistical fit of the combined model, the answer was a clear yes. Likelihood-ratio tests showed significant improvement at both two and three years in the derivation cohort, with p-values below 0.001, and at three years in the external validation cohort, with a p-value of 0.031. In practical terms, this means the imaging model captures prognostic information that the pathological score cannot, offering genuinely incremental value precisely at the longer follow-up horizons that matter most for treatment planning.

The team also confronted the messy realities of real-world oncology data through sensitivity analyses. Two potential confounders loomed large: persistent postoperative PSA, which may reflect incomplete tumour resection rather than true recurrence, and secondary treatments such as salvage radiotherapy initiated before biochemical recurrence was documented, which can artificially delay the observed endpoint. Reassuringly, the two imaging-derived predictors, ADCmin-TBR and TMR, remained directionally stable across all sensitivity analyses, suggesting their prognostic signal is robust to these distortions. The PET/MR T-stage effect, however, was attenuated after treatment censoring, a finding the authors interpret as evidence that imaging-based staging may partly capture disease biology that secondary treatment subsequently modifies. This nuance underscores why the researchers caution that prospective validation is required before the model can guide secondary-treatment decisions in routine practice.

The implications of the study extend well beyond the statistics. If a preoperative PET/MR scan can identify patients at high risk of recurrence, surgeons could tailor the extent of lymph node dissection, radiation oncologists could escalate or de-escalate adjuvant therapy, and patients could be stratified into trials of intensified systemic treatment. The fluorine-18 label of PSMA-1007 also carries practical advantages over gallium-68 based tracers, including a longer half-life of roughly 110 minutes that permits central radiopharmacy production and wider distribution, potentially making the approach scalable beyond specialised academic centres. Previous work has already established that high PSMA expression correlates with early PSA recurrence and that PET-based tumour segmentation predicts survival in the recurrent setting, but this study is among the first to combine metabolic, diffusion, and staging information from a single hybrid examination into an externally validated preoperative model.

Challenges remain before the model reaches the clinic. The retrospective design, the modest validation cohort of 60 patients, and the predominance of Chinese centres all warrant broader prospective testing across diverse populations. Radiomic features are also sensitive to scanner vendor, acquisition protocol, and reconstruction parameters, so multicentre harmonisation will be essential. Yet the direction of travel is unmistakable. Medicine is steadily moving from reactive diagnosis toward predictive, imaging-driven risk stratification, and this study demonstrates that a single preoperative hybrid scan can carry enough quantitative information to forecast the trajectory of prostate cancer years before PSA betrays the first sign of relapse. For patients facing the anxious arithmetic of post-surgical surveillance, that prospect transforms a routine PET/MR examination into something far more powerful: a crystal ball built from physics, chemistry, and statistics, refined by data from 210 patients and validated across three hospitals.

Subject of Research: Preoperative 18F-PSMA-1007 PET/MR prognostic modelling for predicting biochemical recurrence after radical prostatectomy in prostate cancer

Article Title: Development and validation of a preoperative 18F-PSMA-1007 PET/MR prognostic model for predicting biochemical recurrence in prostate cancer: a multicentre study

Article References: Hu, J., Chunyu, H., Yang, Y., Song, Y., Cheng, C., Tang, H., Chen, X., Cheng, R., Dai, J., Meng, H., Zuo, C., Zhao, J., & Li, B. (2026). Development and validation of a preoperative 18F-PSMA-1007 PET/MR prognostic model for predicting biochemical recurrence in prostate cancer: a multicentre study. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-026-08179-5

Image Credits: AI Generated

DOI: 10.1007/s00259-026-08179-5

Keywords: prostate cancer, PSMA PET, 18F-PSMA-1007, PET/MR, biochemical recurrence, radical prostatectomy, prognostic model, radiomics, CAPRA-S, LASSO-Cox regression, multicentre study, molecular imaging

The concept of oligometastatic disease sits at one of the most consequential fault lines in modern oncology. It describes an intermediate state in which cancer has spread beyond the primary organ but only to a small number of sites, conventionally defined in this study as three or fewer metastatic lesions. Unlike widespread metastatic disease, which is managed with systemic therapy aimed at control rather than cure, oligometastatic prostate cancer may be amenable to metastasis-directed therapies such as stereotactic body radiotherapy or surgery targeting individual lesions. Randomized trials including STOMP and ORIOLE have suggested that ablating these limited deposits can delay progression, and trials such as ARTO and RADIOSA have explored combining such approaches with hormonal therapy. But every one of these strategies depends on one thing: knowing exactly which patients truly have only a handful of metastases. That is where the accuracy of the staging scan becomes decisive.

PSMA-PET works on a fundamentally different principle from conventional imaging. Rather than relying on anatomical changes, such as an enlarged lymph node or a bone lesion visible on a scintigram, it uses a radioactive tracer that binds to prostate-specific membrane antigen, a molecule abundantly expressed on the surface of most prostate cancer cells. When injected intravenously, the labeled ligand accumulates in PSMA-expressing tissue, and the PET scanner maps this molecular signal across the whole body, typically fused with computed tomography for anatomical correlation. The result is a functional image that can reveal metastases only a few millimeters in size, long before they distort anatomy enough to be caught by CT or bone scan. Joint procedure guidelines from the European Association of Nuclear Medicine and the Society of Nuclear Medicine and Molecular Imaging, along with standardized reporting frameworks such as E-PSMA and PROMISE version 2, have progressively codified how these scans should be acquired and interpreted.

To test how this translates into everyday clinical practice, the researchers assembled a retrospective cohort of 497 patients with intermediate- to high-risk prostate cancer drawn from multiple centers. Of these, 255 men had undergone both PSMA-PET and conventional imaging within a four-month window, satisfying the strict inclusion criteria for the primary analysis. The primary endpoint was the detection rate of oligometastatic disease, defined as three or fewer metastatic sites, under each modality. The secondary endpoint examined whether the PSMA-PET findings altered the intended clinical management, as judged by a retrospective multidisciplinary review of each case.

The numbers tell a clear story. PSMA-PET identified oligometastatic disease in 11.4 percent of the analyzed patients, or 29 of 255 men, compared with just 6.7 percent, or 17 of 255, using conventional imaging, a difference that reached statistical significance with a p-value of 0.040. In other words, for every hundred men staged with conventional scans alone, roughly five who actually harbored limited metastatic disease would have been misclassified as having localized cancer. The molecular technique also detected more patients with multimetastatic disease, meaning widespread spread beyond the oligometastatic threshold. This pattern of reclassification, in which a more sensitive test shifts patients into more advanced disease categories, is what epidemiologists call stage migration, and it has profound implications for how clinical statistics and treatment decisions are framed.

Perhaps the most clinically resonant finding concerned treatment planning. When a multidisciplinary panel re-reviewed each case in light of the PSMA-PET results, the intended management changed in 36.5 percent of patients, or 93 of the 255 studied. These changes split roughly evenly into major and minor categories, each accounting for about 18 percent of the cohort. A major change typically meant a fundamental shift in therapeutic strategy, for example abandoning a planned curative treatment such as radical surgery or radiotherapy in favor of systemic therapy once previously invisible metastases came to light. Minor changes included adjustments within a general strategy, such as modifying the radiation field or adding hormonal therapy. The authors are careful to note that these figures reflect the intended treatment plan rather than the treatment actually delivered, an important distinction given the retrospective design.

The study’s authors are equally candid about its limitations, and understanding them is essential to interpreting the results correctly. Because the analysis was retrospective, there was no independent reference standard, such as histopathological confirmation of every detected lesion, against which the two imaging modalities could be judged. No central review of the images was performed, meaning scans were interpreted at the originating institutions under routine conditions. Crucially, no patient follow-up was available, so the study cannot say whether the additional detections by PSMA-PET translate into longer survival or better disease control. The authors explicitly state that their findings demonstrate increased detection and reclassification, not proven improvements in diagnostic accuracy or outcomes. This is a common and honest caveat in the stage migration literature: a more sensitive test will always find more disease, but only longitudinal data can confirm that finding it earlier and more completely helps patients live longer.

Even with those caveats, the results align with a growing body of prospective evidence. The landmark proPSMA trial, published in The Lancet in 2020, randomized men with high-risk prostate cancer to PSMA-PET or conventional imaging before curative-intent treatment and found superior accuracy for the molecular approach. Subsequent work has shown that PSMA-PET-guided staging is potentially cost-effective in European and American health systems, and diagnostic accuracy studies have confirmed high sensitivity for pelvic nodal metastases prior to radical prostatectomy. On the therapeutic side, the same PSMA target has been exploited for treatment, most notably with lutetium-177-PSMA-617 radioligand therapy, which improved survival in metastatic castration-resistant prostate cancer in a landmark New England Journal of Medicine trial. The imaging and therapeutic applications of PSMA thus form a theranostic pipeline in which the molecule that reveals the cancer also becomes the vehicle for destroying it.

Why does accurate identification of oligometastatic disease matter so much right now? Because the treatment landscape for advanced prostate cancer is fragmenting into increasingly tailored options. Men with de novo metastatic hormone-sensitive disease benefit from intensification strategies, including androgen deprivation therapy combined with docetaxel or androgen receptor pathway inhibitors such as abiraterone and darolutamide, as established by trials including CHAARTED, LATITUDE, PEACE-1 and ARASENS. Men with limited metastatic disease, by contrast, may be candidates for metastasis-directed therapy, potentially avoiding or deferring systemic side effects. The boundary between these populations is exactly where PSMA-PET is drawing a sharper line. If conventional imaging leaves oligometastatic patients hidden within the localized cohort, they may receive curative-intent local therapy that cannot address their occult spread. If it leaves them hidden within the multimetastatic cohort, they may receive systemic therapy forgoing potentially curative ablative treatment. Either misclassification carries a cost.

The practical consequence of this study is likely to be a strengthening of the case for PSMA-PET as the default staging modality for intermediate- and high-risk prostate cancer, a position already reflected in contemporary European Association of Urology guidelines. For patients, the message is that the type of staging scan they receive can genuinely determine which treatment pathway they are offered. For clinicians and trialists, the stage migration documented here means that historical survival statistics, which were built on conventional imaging cohorts, cannot be directly compared with outcomes in PSMA-PET-era populations, since the same label now describes patients with different underlying disease burdens. Future prospective studies with long-term follow-up will need to establish whether reclassifying these men improves survival. What this real-world analysis establishes today is simpler but consequential: the scans that medicine relied on for decades were missing metastatic disease in a meaningful fraction of men, and a molecular imaging technique that sees what those scans cannot is already changing the plan of care for more than one in three patients.

Subject of Research: The role of PSMA-PET in detecting oligometastatic prostate cancer and driving stage migration compared with conventional imaging

Article Title: Stage migration in prostate cancer: the role of PSMA-PET in identifying oligometastatic disease

Article References: Mattana, F., Luzzago, S., Dragonetti, V., Kasivisvanathan, V., Conlon, S., Castellucci, P., Farolfi, A., Miszczyk, M., Techmański, T., Rajwa, P., Shariat, S. F., Zattoni, F., Reitano, G., Briganti, A., Montorsi, F., Frassoni, S., Bagnardi, V., Gandaglia, G., & Ceci, F. (2026). Stage migration in prostate cancer: the role of PSMA-PET in identifying oligometastatic disease. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-026-08166-w

Image Credits: AI Generated

DOI: 10.1007/s00259-026-08166-w

Keywords: prostate cancer, PSMA-PET, oligometastatic disease, stage migration, nuclear medicine, cancer staging, metastasis-directed therapy, conventional imaging, molecular imaging, stereotactic body radiotherapy, theranostics, clinical staging

The study, published in the European Journal of Nuclear Medicine and Molecular Imaging, enrolled fifty men with biopsy-proven high-risk prostate cancer scheduled for robot-assisted radical prostatectomy between January 2022 and July 2024. Every participant underwent both [18F]F-PSMA-1007 PET/CT and [68Ga]Ga-PSMA-11 PET/CT before surgery, and forty-five also received multiparametric MRI after a protocol amendment added it as an exploratory third modality. The researchers then mapped tumours across six anatomical sextants of the prostate—base, mid-gland and apex on each side—using whole-mount histopathology of the entirely embedded surgical specimen, in which the gland is sectioned into 5 to 6 millimetre slices, embedded in paraffin, cut at 4 to 5 micrometres and stained for microscopic examination by two blinded uropathologists.

The underlying biology makes PSMA PET a compelling candidate for this task. Prostate-specific membrane antigen is a protein abundantly displayed on the surface of prostate cancer cells, and radiolabelled ligands that bind it allow clinicians to visualise tumour deposits as bright focal spots against dimmer background tissue. The two tracers differ chemically: gallium-68 is produced in a generator and has a half-life of just over an hour, while fluorine-18 offers a longer half-life of about 110 minutes, lower positron energy that yields sharper images, and reduced urinary excretion that can keep the bladder from obscuring the prostate. These theoretical advantages have fuelled a long-standing debate about which ligand clinicians should prefer.

The Danish team’s answer, at least within this cohort, is that it barely matters. At the patient level, [18F]F-PSMA-1007 PET/CT detected clinically significant prostate cancer—defined as grade group 3 or higher, or grade group 2 with a tertiary Gleason pattern 5—with 98 percent sensitivity and 96 percent diagnostic accuracy. [68Ga]Ga-PSMA-11 achieved 100 percent sensitivity and 98 percent accuracy, while MRI reached 96 percent sensitivity and 93 percent accuracy. No statistically significant difference separated the two PSMA ligands. The single apparent false-positive PET finding turned out to reflect tracer uptake in lower-grade, clinically insignificant cancer rather than benign tissue, underscoring how faithfully PSMA signal tracks with malignant biology even when it overshoots the clinical threshold.

The regional analysis told a more nuanced story. Of 300 prostate sextants, 205 contained clinically significant cancer. [18F]F-PSMA-1007 correctly identified clinically significant disease in 143 sextants, yielding a mixed-model accuracy of 69.8 percent, while [68Ga]Ga-PSMA-11 detected 136 sextants with 67.8 percent accuracy. MRI, evaluated across 270 sextants, achieved 62.9 percent accuracy. The statistical modelling, which used mixed-effects regression with a random intercept per patient to account for the clustering of repeated measurements within each prostate, revealed a striking trade-off: both PSMA tracers were significantly more sensitive than MRI, at roughly 70 percent versus 51 percent, but MRI was significantly more specific, at nearly 89 percent versus about 68 percent for the PET ligands. In other words, PSMA PET finds more of the tumour, while MRI makes fewer false alarms.

That complementarity is the study’s most clinically resonant finding. MRI, the current guideline-endorsed standard for tumour localisation and surgical planning, excels at anatomical detail but can miss lesions obscured by motion artefacts, hip prostheses, or inflammation, and it systematically underestimates tumour extent. PSMA PET, by contrast, lights up malignant tissue with high tumour-to-background contrast but flags some regions that turn out to harbour only low-grade disease. The authors argue that the two technologies may work best together, a conclusion that aligns with emerging multimodal approaches in which artificial intelligence models integrate PSMA PET, MRI, and clinical variables to predict adverse pathology before surgery.

Where both technologies stumbled was in staging tumour extension beyond the prostate gland. Extraprostatic extension was present in 26 of the 50 patients, yet sensitivity for detecting it was a dismal 12 percent for [18F]F-PSMA-1007, 23 percent for [68Ga]Ga-PSMA-11, and 9 percent for MRI. Seminal vesicle invasion, present in ten patients, fared somewhat better but still poorly, with both PET tracers reaching 30 percent sensitivity and MRI 14 percent—though specificity was nearly perfect, meaning that when any modality did call invasion, it was almost always right. These sobering numbers suggest that neither PSMA PET nor MRI is ready to replace histopathological assessment for local T-staging, and that surgical decisions about nerve-sparing must still rest on a synthesis of imaging, biopsy data and clinical judgement.

The study’s methodological rigour deserves emphasis. It followed STARD reporting guidelines, was registered in the EudraCT database, and was monitored under Good Clinical Practice. Readers were blinded to clinical data, histopathology and the other imaging modalities, and each reader interpreted only a single modality, with equivocal findings resolved by consensus. The researchers applied the PROMISE standardised reporting criteria for PSMA PET, using the liver as the reference background for the gallium tracer and the spleen for the fluorine tracer, and scored MRI lesions with PI-RADS version 2.1, counting regions as positive only at scores of 4 or higher. A neighbouring-region approach was used to minimise spatial mismatch between in-vivo imaging and ex-vivo pathology, acknowledging the tissue deformation and shrinkage that inevitably occur between scanning and sectioning.

The authors are careful about what their results do and do not prove. The study was designed to detect differences between modalities, not to formally demonstrate equivalence, so the absence of a statistically significant gap between the two PSMA ligands should not be read as proof of interchangeability. The single-centre design, the modest sample size, and the enrolment of patients from a high-volume tertiary centre all limit generalisability, and the MRI comparison was exploratory rather than prespecified. Still, the head-to-head design within the same patients, validated against whole-mount histopathology, is rare, and the findings provide hypothesis-generating evidence that both ligands perform comparably for intraprostatic localisation.

The implications ripple outward as PSMA PET expands from its established role in staging recurrent and metastatic disease toward primary tumour characterisation. If fluorine-18 and gallium-68 tracers deliver comparable intraprostatic performance, supply chains, costs and local production capacity may weigh more heavily in tracer selection than diagnostic nuance. Meanwhile, the demonstrated sensitivity advantage of PSMA PET over MRI, paired with MRI’s specificity edge, strengthens the case for hybrid and multimodal strategies that fuse molecular and anatomical information. As deep-learning models increasingly promise individualised risk stratification from combined imaging, this study supplies an essential foundation: a carefully validated account of what each modality, and each tracer, can and cannot see inside the prostate gland.

Subject of Research: Head-to-head comparison of two PSMA PET tracers and MRI for detecting and localising clinically significant prostate cancer against histopathology

Article Title: Head-to-head comparison of [¹⁸F]F-PSMA-1007 PET/CT and [⁶⁸Ga]Ga-PSMA-11 PET/CT for intraprostatic tumour detection and localisation using histopathology as reference: A prospective single-centre diagnostic accuracy study

Article References: Gossili, F., Harving, F., Petersen, A. C., Madsen, C., Bouchelouche, K., Bruun, N. H., Leusink, R. J., Ahmed, A., Laursen, A. M., & Zacho, H. D. (2026). Head-to-head comparison of [¹⁸F]F-PSMA-1007 PET/CT and [⁶⁸Ga]Ga-PSMA-11 PET/CT for intraprostatic tumour detection and localisation using histopathology as reference: A prospective single-centre diagnostic accuracy study. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-026-08191-9

Image Credits: AI Generated

DOI: 10.1007/s00259-026-08191-9

Keywords: PSMA PET, prostate cancer, PET/CT, multiparametric MRI, F-18 PSMA-1007, Ga-68 PSMA-11, histopathology, tumour localisation, diagnostic accuracy, radical prostatectomy, nuclear medicine, PI-RADS

One of the most conceptually striking studies targets the tumor microenvironment itself. Researchers developed and evaluated a PET imaging approach aimed at CD163, a surface marker carried by tumor-associated macrophages, the immune cells that tumors frequently recruit and reprogram to support their own growth. In head and neck squamous cell carcinoma, a malignancy in which the immune landscape often determines how patients respond to therapy, a tracer labeled with copper-64, known as 64Cu-ICT-01, allowed investigators to visualize where these macrophages reside and how their distribution shifts during tumor progression and after treatment. Complementary testing on human tissue confirmed that the tracer binds specifically to CD163, supporting its translational relevance. If validated further, the technique could give oncologists a noninvasive window into immunosuppressive niches within tumors, potentially helping predict which patients will benefit from immunotherapy long before changes in tumor size become apparent.

Theranostics, the pairing of diagnostic imaging with targeted radionuclide therapy, features prominently in the new research. A prospective clinical trial evaluated 177Lu-LNC1010, a long-acting somatostatin analog labeled with lutetium-177, for peptide receptor radionuclide therapy in 22 patients with progressive metastatic neuroendocrine tumors. Long-acting formulations are designed to prolong tumor exposure to the therapeutic radiation while simplifying treatment logistics, and in this trial patients received up to four cycles. The investigators systematically assessed safety, tumor response, absorbed radiation doses delivered to tumors and organs at risk, progression-free survival and overall survival during follow-up. The results add to rapidly growing evidence that radioligand therapy can deliver clinically meaningful disease control in neuroendocrine tumors, a class of cancers that has historically been difficult to treat with conventional chemotherapy.

A second radiopharmaceutical study turned its attention to CEACAM5, a cell-surface protein overexpressed in several cancers, including colorectal cancer, and an established target for both antibody-drug conjugates and radioligand therapy. In laboratory and mouse experiments, a radiolabeled compound designed to bind CEACAM5 selectively attached to CEACAM5-positive cancer cells while demonstrating favorable tumor uptake and reduced accumulation in the kidneys, a critical safety consideration for peptide- and antibody-based radionuclide therapies. Remarkably, a single treatment significantly extended survival in mice bearing CEACAM5-positive tumors, with only mild and temporary toxicity observed. The findings position this agent as a candidate for translation into first-in-human trials and reinforce the broader trend of matching radiopharmaceuticals to molecular signatures rather than tumor locations.

Pediatric oncology also gained a potential new target. Neuroblastoma, an aggressive cancer of the sympathetic nervous system that primarily affects young children, remains one of the most challenging malignancies to image and treat. Researchers examined DLL3, a protein better known from small cell lung cancer, as a candidate target in neuroblastoma. Analysis of human tumor samples and preclinical models revealed that DLL3 is widely expressed and frequently localized on the cell surface, an essential prerequisite for both imaging agents and therapeutic radioligands. DLL3-targeted PET imaging subsequently demonstrated tumor-specific uptake not only in preclinical models but also in four patients with relapsed neuroblastoma, offering early clinical proof of concept. For children with few remaining options, a validated DLL3 pathway could open the door to both molecular imaging and precision radioligand therapy in the future.

Beyond theranostics, several new studies interrogate the reliability of the workhorse technology of molecular imaging itself. Amyloid PET, used to detect the amyloid plaques characteristic of Alzheimer’s disease, has become central to diagnosis and to the growing field of disease-modifying Alzheimer’s therapy. A study of nearly 1,500 amyloid PET scans compared interpretations by local radiologists and nuclear medicine physicians with those of expert readers across three FDA-approved tracers. The good news: agreement was consistently strong, with similar performance for positive and negative scans. Importantly, the study also found that lower reader confidence was associated with reduced agreement, suggesting that confidence ratings could serve as a quality-control signal in routine practice. As amyloid PET demand surges worldwide, the findings provide reassurance that community-based interpretation can keep pace with expert standards.

Prostate cancer, the most active arena in nuclear medicine today, received an unusually detailed quantitative treatment. In a multicenter study, researchers evaluated measurements derived from 18F-piflufolastat PSMA PET/CT, matching PET findings with histopathology from 305 men to determine which imaging metrics best distinguish malignant prostate cancer from benign tissue. Several quantitative measures correlated with malignancy, but the SUVmax-to-blood-pool ratio showed the strongest ability to separate cancerous from benign lesions, both within the prostate and at metastatic sites. Establishing such thresholds is a critical step toward standardizing PSMA PET interpretation, reducing unnecessary biopsies, and enabling radiologists to report results with quantitative, reproducible criteria rather than subjective visual assessment alone.

Combination therapy, meanwhile, may soon be guided by a simple blood test and a PET scan. In an analysis of 37 patients with metastatic castration-resistant prostate cancer receiving 177Lu-PSMA-617 together with pembrolizumab, an immune checkpoint inhibitor, researchers examined whether baseline biomarkers could predict response. Patients with lower levels of circulating tumor DNA at the start of treatment and higher PSMA uptake on PET fared better, while changes in circulating tumor DNA and PSMA PET measurements at 12 weeks reflected both the depth and durability of response. The study points toward a practical biomarker strategy for selecting patients for combined radioligand immunotherapy, one of the most closely watched approaches in advanced prostate cancer.

Breast and kidney cancer imaging rounded out the new research portfolio. In triple-negative breast cancer, the most aggressive breast cancer subtype, a study compared 18F-ATD001, a PARP-targeted PET tracer, with standard 18F-FDG PET/CT in 37 women. The two methods detected similar numbers of lesions, and although the PARP tracer showed lower overall uptake, its signal correlated moderately with FDG in primary tumors, suggesting it may provide complementary biological information about DNA repair enzyme expression that FDG cannot capture. Separately, a prospective study of 68Ga-DPI-4452, a tracer targeting carbonic anhydrase IX, evaluated 30 adults with suspected kidney tumors. The agent identified clear cell renal cell carcinoma with high sensitivity and detected substantially more metastatic lesions than conventional imaging, with tracer uptake strongly correlating with CAIX expression in tumor tissue, a combination of diagnostic accuracy and biological validation that could reshape renal cancer imaging.

Taken together, the ahead-of-print collection paints a picture of a field in confident ascent. Tracers are becoming more biologically specific, imaging metrics are being quantified against gold-standard pathology, and therapy is increasingly delivered by molecules that home in on cancer cells while sparing healthy tissue. From macrophage mapping in head and neck cancer to DLL3 imaging in children with relapsed neuroblastoma, the studies collectively advance the central promise of nuclear medicine and theranostics: diagnosing and treating each patient according to the unique molecular fingerprint of their disease, with the goal of achieving the best possible outcomes.

Subject of Research: Advances in molecular imaging and radiopharmaceutical therapy reported in The Journal of Nuclear Medicine ahead-of-print research

Article Title: The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: September 11, 2026

Article References: The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: September 11, 2026. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: nuclear medicine, PET imaging, theranostics, radiopharmaceutical therapy, PSMA PET, neuroendocrine tumors, neuroblastoma, amyloid PET, prostate cancer, triple-negative breast cancer, kidney cancer, tumor-associated macrophages